Our data suggest that patients positive for anti-GAD65 should be screened for anti-CN1A-associated diseases, and that a more comprehensive evaluation of anti-CN1A in anti-GAD65-associated autoimmune diseases (e.g. T1DM, vitiligo, Hashimoto’s thyroiditis) may clarify the links between systemic autoimmunity and epilepsy. This evidence concerns the gene GAD2 and epilepsy.